(3.236.117.38)
Users online: 3151    [ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2019, Volume : 12, Issue : 12
First page : ( 5716) Last page : ( 5722)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2019.00989.2

Pleiotropic Repositioning of Metformin as a Potential Pluripotent Drug

Ayoub Bassam M*

The Center for Drug Research and Development (CDRD), Pharmaceutical Chemistry Department Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo, 11837, Egypt

*Corresponding Author E-mail: bassam.ayoub@bue.edu.eg

Online published on 24 February, 2020.

Abstract

Metformin repositioning is a hot interesting topic and valuable substitute to molecular target based drug discovery as therapeutic switching using off-target strategy. It is a relatively inexpensive pathway due to availability of previous pharmacological and safety data. The author performed a Scopus database literature review of articles published on repositioning of metformin with special consideration of all details published on 2016, 2017 and 2018 as the latest updated literature that described concisely metformin as a potential pleiotropic multi-therapeutic agent. The repositioning of already a marketed anti-diabetic drug saves the high cost of the time-consuming normal drug development process for the other mentioned pharmacological activities. Metformin inhibits dyskinesia in Parkinson's disease, cancer recurrence, neuroendocrine tumors, colorectal carcinoma, prostate cancer, breast cancer, pancreatic cancer, cholangiocarcinoma, fibrosarcoma and even enhancing the healing process for liver injury, cardiovascular disease and Fragile X syndrome. Metformin is beneficial for neurodegenerative diseases especially Alzheimer disease. And it up regulates neurotrophic factor and prevents dopaminergic neuron death in Parkinson's model. As one of the most frequently used oral antidiabetic drugs, it also improves serum lipid profiles, positively influences hemostasis, cognitive impairment and possesses anti-inflammatory properties. Results of several clinical studies confirm that long term use of metformin in diabetic patients contributes to better cognitive function, compared to participants using other antidiabetic drugs. This supports the position of metformin as first-line therapy and implies that metformin may confer benefit in non-diabetics.

Top

Keywords

Repositioning, Metformin, pleiotropic, multi-therapeutic.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
497,508,463 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.